clinical trial · NCT03952559
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
Eli Lilly and Company·phase3·active not recruiting·n = 516
Atopic DermatitisBaricitinibPlaceboTopical corticosteroid
brief summary
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
started
May 24, 2019
primary completion
Apr 24, 2022
completion
May 1, 2026
last updated
Apr 24, 2026
official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol